Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Diagonal Therapeutics Secures $128 Million in Financing

2024-04-03
CAMBRIDGE, MA, Diagonal Therapeutics launched with $128 million in financing. The Series A was co-led by BVF Partners and Atlas Venture.
Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, launched today with $128 million in financing. The Series A was co-led by BVF Partners and Atlas Venture, with participation from Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, Velosity Capital, and Checkpoint Capital. Diagonal was co-founded by Chief Executive Officer, Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors